drugset / Trial / NCT06089278
A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.
Phase 2
Completed
160 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.
Timeline
- Start
- 2023-12-28
- Primary completion
- 2025-03-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQH2722 | Monoclonal antibody | 300 mg | — |
| Subject | TQH2722 | Monoclonal antibody | 600 mg | — |